Results 221 to 230 of about 62,013 (267)

Acute Severe Ulcerative Colitis (ASUC): Clinical Features, Initial Management, and the Role of Advanced Therapies. [PDF]

Biomedicines
Jamal F, Ivanov M, Elmasry S, Gonzalez AJ, Malik TA.   +4 more
europepmc   +1 more source

Adalimumab as a Potential Therapeutic Option for Metastatic Crohn's Disease With Genital Lesions and Edema: A Case Report. [PDF]

Clin Case Rep
Haghshenas H, Darban B, Bagherzadeh MA, Karimi M, Ataollahi M.   +4 more
europepmc   +1 more source

Clinical outcomes of giant coronary aneurysms in South Asian children with Kawasaki disease. [PDF]

Pediatr Rheumatol Online J
Abhinav K, Selvam N, Kumar RK, Bhattacharya A, Pradeep M, Balan S.   +5 more
europepmc   +1 more source

Validation of a model of rheumatoid arthritis using mice reconstituted with patient peripheral blood mononuclear cells.

Dis Model Mech
Schuster-Winkelmann P, Weß V, Schindler M, Jensen MØ, Shaw DE, Alberton P, Schulze-Koops H, Schoenthaler S, Weinhaeusel A, Siebeck M, Gropp R, Aszodi A.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Infliximab

Drugs, 2005
Infliximab is a monoclonal antibody that binds to tumour necrosis factor-alpha and blocks its biological activity. It is approved for use in patients with rheumatoid arthritis, Crohn's disease and ankylosing spondylitis.black triangle In well designed, placebo-controlled trials of 12 or 24 weeks' duration in patients with active ankylosing spondylitis,
Dean M, Robinson, Gillian M, Keating
openaire   +3 more sources

Infliximab

Dermatologic Therapy, 2004
Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF-alpha in the immunopathogenesis of ...
Laura S, Winterfield, Alan, Menter
openaire   +2 more sources

Infliximab

Expert Opinion on Pharmacotherapy, 2001
Infliximab (Remicade, Centocor, Inc.) is an intravenously administered monoclonal antibody to TNF proven effective in the treatment of moderate to severe Crohn's disease (CD). Its introduction in October 1998 was heralded by some as the most important addition to therapy for this condition in 50 years. Since then, additional indications have been added
E, Valle, M, Gross, S J, Bickston
openaire   +2 more sources

Infliximab

Annales de Dermatologie et de Vénéréologie, 2011
C, Goujon, H, Bachelez
  +8 more sources